secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001753926-23-000382
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella completes Phase 2a trial of LP-10 for hemorrhagic cystitis; reports $5.1M cash, IPO completed
--------------------------------------------------------------------------------

- Completed Phase 2a trial of LP-10 for hemorrhagic cystitis; top-line results showed no serious adverse events and reduced symptoms.
- Year-end cash $5.1M, provides operating runway into 2024.
- Appointed Douglas Johnston as CFO in November 2022.
- Completed IPO and Nasdaq listing in December 2022.
- Created Oral Health Scientific Advisory Board for LP-310; results to be presented at AUA meeting April 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392623000382/0001753926-23-000382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392623000382/g083471_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-23-000382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer